Skip to main content
Premium Trial:

Request an Annual Quote

Australian Firm Taps Dotmatics Platform to ID Oncology Drug Candidates

Premium

Cancer Therapeutics CRC, a small-molecule drug discovery company based in Bundoora, Australia, has selected Dotmatics' informatics platform to provide tools for querying and analyzing data at its research sites.

Cancer Therapeutics CRC focuses on generating lead and preclinical-stage drug candidates. In particular, it looks for potential treatments that target cancer pathways associated with the tumor microenvironment or growth in breast, prostate, melanoma, lung, and brain cancers.

The firm has selected Dotmatics' Browser and Vortex programs to support data sharing and communication with its academic, research, and industrial partners; and to increase its research output.

Last month, Dotmatics announced that Progenra, a Malvern, Penn.-based biotechnology company, had licensed its informatics platform to support drug discovery and development efforts around the ubiquitin-proteasomal pathway of cellular protein regulation (BI 5/25/2012).

Also in May, Basilea Pharmaceutica, a Swiss biopharmaceutical company, licensed the Dotmatics platform to manage its preclinical research data (BI 5/18/2012).

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.